Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||gastric adenocarcinoma||not applicable||Capecitabine + Oxaliplatin + Toripalimab||Phase II||Actionable||In a Phase II trial, Toripalimab (JS001) in combination with Xeloda (capecitabine) and Eloxatin (oxaliplatin) resulted in an objective response rate of 54.5% (18/33) and a disease control rate of 84.8% (28/33) in patients with metastatic gastric adenocarcinoma, with a median duration of response of 8.3 months (J Clin Oncol 38: 2020 (suppl; abstr e15083); NCT02915432).||detail...|
|PubMed Id||Reference Title||Details|
|Clinical response and biomarker analysis of a phase II basket trial of toripalimab, a PD-1 mAb in combination with standard chemotherapy as a first-line treatment for patients with solid tumors.||Full reference...|